The fitness costs of antibiotic resistance mutations

Evolutionary Applications

Volumn 8, Issue 3, 2015, Pages 273-283

  Melnyk, Anita H ^a   Wong, Alex ^b   Kassen, Rees ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b CARLETON UNIVERSITY   (Canada)

Author keywords

Adaptation; Antibiotic resistance; Fitness

Indexed keywords

EID: 84925343017     PISSN: 17524563     EISSN: 17524571     Source Type: Journal    
DOI: 10.1111/eva.12196     Document Type: Article

References (73)

1. Andersson, D. I. 2003. Persistence of antibiotic resistant bacteria. Current Opinion in Microbiology 6:452-456.
2. Andersson, D. I. 2006. The biological cost of mutational antibiotic resistance: any practical conclusions? Current Opinion in Microbiology 9:461-465.
3. Andersson, D. I., and D. Hughes 2010. Antibiotic resistance and its cost: is it possible to reverse resistance? Nature Reviews Microbiology 8:260-271.
4. Arason, V., A. Gunnlaugsson, J. Sigurdsson, H. Erlendsdottir, S. Gudmundsson, and K. G. Kristinsson 2002. Clonal spread of resistant Pneumococci despite diminished antimicrobial use. Microbial Drug Resistance 8:187-192.
5. Austin, D. J., K. G. Kristinsson, and R. M. Anderson 1999. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proceedings of the National Academy of Sciences 96:1152-1156.
6. Balsalobre, L., and A. G. de la Campa 2008. Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes. Antimicrobial Agents and Chemotherapy 52:822-830.
7. Bataillon, T., T. Zhang, and R. Kassen 2011. Cost of adaptation and fitness effects of beneficial mutations in Pseudomonas fluorescens. Genetics 189:939-949.
8. Bergman, M., S. Huikko, M. Pihlajamäki, P. Laippala, E. Palva, P. Huovinen, and H. Seppälä 2004. Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001. Clinical Infectious Diseases 38:1251-1256.
9. Billington, O. J., T. D. McHugh, and S. H. Gillespie 1999. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 43:1866-1869.
10. Binet, R., and A. T. Maurelli 2005. Fitness cost due to mutations in the 16S rRNA associated with spectinomycin resistance in Chlamydia psittaci 6BC. Antimicrobial Agents and Chemotherapy 49:4455-4464.
11. Björkholm, B., M. Sjölund, P. G. Falk, O. G. Berg, L. Engstrand, and D. I. Andersson 2001. Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. Proceedings of the National Academy of Sciences of the United States of America 98:14607-14612.
12. Björkman, J., I. Nagaev, O. G. Berg, D. Hughes, and D. I. Andersson 2000. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287:1479-1482.
13. Borrell, S., Y. Teo, F. Giardina, E. M. Streicher, M. Klopper, J. Feldmann, B. Muller et al. 2013. Epistasis between antibiotic resistance mutations drives the evolution of extensively drug-resistant tuberculosis. Evolution, Medicine, and Public Health 2013:65-74.
14. Böttger, E. C., B. Springer, M. Pletschette, and P. Sander 1998. Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nature Medicine 4:1343-1344.
15. Bryskier, A. 2005. Antimicrobial Agents: Antibacterials and Antifungals. ASM Press, Washington DC.
16. Comas, I., S. Borrell, A. Roetzer, G. Rose, B. Malla, M. Kato-Maeda, J. Galagan et al. 2011. Whole-genome sequencing of rifampicin-resistant M. tuberculosis strains identifies compensatory mutations in RNA polymerase. Nature Genetics 44:106-110.
17. Conly, J. 2002. Antimicrobial resistance in Canada. Canadian Medical Association Journal 167:885-891.
18. Criswell, D., V. L. Tobiason, J. S. Lodmell, and D. S. Samuels 2006. Mutations conferring aminoglycoside and spectinomycin resistance in Borrelia burgdorferi. Antimicrobial Agents and Chemotherapy 50:445-452.
19. Davies, J., and D. Davies 2010. Origins and evolution of antibiotic resistance. Microbiology and Molecular Biology Reviews 74:417-433.
20. Dykhuizen, D. E., and D. L. Hartl 1983. Selection in chemostats. Microbiology Reviews 47:150-168.
21. Ender, M., N. Mccallum, R. Adhikari, and B. Berger-Bächi 2004. Fitness cost of SCCmec and methicillin resistance levels in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 48:2295-2297.
22. Enne, V. I. 2010. Reducing antimicrobial resistance in the community by restricting prescribing: can it be done? The Journal of Antimicrobial Chemotherapy 65:179-182.
23. Enne, V. I., D. M. Livermore, P. Stephens, and L. M. Hall 2001. Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet 357:1325-1328.
24. Enne, V. I., A. A. Delsol, G. R. Davis, S. L. Hayward, J. M. Roe, and P. M. Bennett 2005. Assessment of the fitness impacts on Escherichia coli of acquisition of antibiotic resistance genes encoded by different types of genetic element. The Journal of Antimicrobial Chemotherapy 56:544-551.
25. Gagneux, S., C. Davis Long, P. M. Small, T. Van, G. K. Schoolnik, and B. J. M. Bohannan 2006. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312:1944-1946.
26. Gillespie, S. H., L. L. Voelker, and A. Dickens 2002. Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microbial Drug Resistance 8:79-84.
27. Gottesman, B. S., Y. Carmeli, P. Shitrit, and M. Chowers 2009. Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clinical Infectious Diseases 49:869-875.
28. Gustafsson, I., O. Cars, and D. I. Andersson 2003. Fitness of antibiotic resistant Staphylococcus epidermidis assessed by competition on the skin of human volunteers. The Journal of Antimicrobial Chemotherapy 52:258-263.
29. Hall, B. G. 2004. Predicting the evolution of antibiotic resistance genes. Nature Reviews Microbiology 2:430-435.
30. Hao, H., M. Dai, Y. Wang, D. Peng, Z. Liu, and Z. Yuan 2009. 23S rRNA mutation 2074C conferring high-level macrolide resistance and fitness cost in Campylobacter jejuni. Microbial Drug Resistance 15:239-244.
31. Holberger, L. E., and C. S. Hayes 2009. Ribosomal protein S12 and aminoglycoside antibiotics modulate A-site mRNA cleavage and transfer-messenger RNA activity in Escherichia coli. The Journal of Biological Chemistry 284:32188-32200.
32. Huitric, E., P. Verhasselt, A. Koul, K. Andries, S. Hoffner, and D. I. Andersson 2010. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrobial Agents and Chemotherapy 54:1022-1028.
33. Hurdle, J. G., A. J. O'Neill, E. Ingham, C. Fishwick, and I. Chopra 2004. Analysis of mupirocin resistance and fitness in Staphylococcus aureus by molecular genetic and structural modeling techniques. Antimicrobial Agents and Chemotherapy 48:4366-4376.
34. Johnsen, P. J., J. P. Townsend, T. Bohn, G. S. Simonsen, A. Sundsfjord, and K. M. Nielsen 2009. Factors affecting the reversal of antimicrobial-drug resistance. The Lancet Infectious Diseases 9:357-364.
35. Johnsen, P. J., J. P. Townsend, T. Bohn, G. S. Simonsen, A. Sunsdfjord, and K. M. Nielsen 2011. Retrospective evidence for a biological cost of vancomycin resistance determinants in the absence of glycopeptide selective pressures. Journal of Antimicrobial Chemotherapy 66:608-610.
36. Kassen, R., and T. Bataillon 2006. Distribution of fitness effects among beneficial mutations before selection in experimental populations of bacteria. Nature Genetics 38:484-488.
37. Kugelberg, E., S. Löfmark, B. Wretlind, and D. I. Andersson 2005. Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa. The Journal of Antimicrobial Chemotherapy 55:22-30.
38. Lenski, R. E., M. R. Rose, S. C. Simpson, and S. C. Tadler 1991. Long-term experimental evolution in Escherichia coli. I. Adaptation and divergence during 2, 000 generations. American Naturalist 138:1315-1341.
39. Levin, B. R., M. Lipsitch, V. Perrot, S. Schrag, R. Antia, L. Simonsen, N. M. Walker et al. 1997. The population genetics of antibiotic resistance. Clinical Infections Diseases 24(S1):9-16.
40. Levin, B. R., V. Perrot, and N. Walker 2000. Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 154:985-997.
41. Luangtongkum, T., Z. Shen, V. W. Seng, O. Sahin, B. Jeon, P. Liu, and Q. Zhang 2012. Impaired fitness and transmission of macrolide-resistant Campylobacter Jejuni in its natural host. Antimicrobial Agents and Chemotherapy 56:1300-1308.
42. Luo, N., S. Pereira, O. Sahin, J. Lin, S. Huang, L. Michel, and Q. Zhang 2005. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. Proceedings of the National Academy of Sciences of the United States of America 102:541-546.
43. Macvanin, M., J. Björkman, S. Eriksson, M. Rhen, D. I. Andersson, and D. Hughes 2003. Fusidic acid-resistant mutants of Salmonella enterica serovar Typhimurium with low fitness in vivo are defective in RpoS induction. Antimicrobial Agents and Chemotherapy 47:3743-3749.
44. Macvanin, M., A. Ballagi, and D. Hughes 2004. Fusidic acid-resistant mutants of Salmonella enterica serovar Typhimurium have low levels of heme and a reduced rate of respiration and are sensitive to oxidative stress. Antimicrobial Agents and Chemotherapy 48:3877-3883.
45. Maisnier-Patin, S., O. G. Berg, L. Liljas, and D. I. Andersson 2002. Compensatory adaptation to the deleterious effect of antibiotic resistance in Salmonella typhimurium. Molecular Microbiology 46:355-366.
46. Mariam, D. H., Y. Mengistu, S. E. Hoffner, and D. I. Andersson 2004. Effect of rpoB mutations conferring rifampin resistance in fitness of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 48:1289-1294.
47. Nagaev, I., J. Björkman, D. I. Andersson, and D. Hughes 2001. Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Molecular Microbiology 40:433-439.
48. Nessar, R., J. M. Reyrat, A. Murray, and B. Gicquel 2011. Genetic analysis of new 16S rRNA mutations conferring aminoglycoside resistance in Mycobacterium abscessus. The Journal of Antimicrobial Chemotherapy 66:1719-1724.
49. O'Neill, A. J., T. Huovinen, C. W. G. Fishwick, and I. Chopra 2006. Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence. Antimicrobial Agents and Chemotherapy 50:298-309.
50. O'Sullivan, D. M., T. D. McHugh, and S. H. Gillespie 2005. Analysis of rpoB and pncA mutations in the published literature: an insight into the role of oxidative stress in Mycobacterium tuberculosis evolution? The Journal of Antimicrobial Chemotherapy 55:674-679.
51. Pallecchi, L., A. Bartoloni, E. Riccobono, C. Fernandez, A. Mantella, D. Magnelli, D. Mannini et al. 2012. Quinolone resistance in absence of selective pressure: the experience of a very remote community in the Amazon forest. PLoS Neglected Tropical Diseases 6:e1790.
52. Palumbi, S. R. 2001. Humans as the world's greatest evolutionary force. Science 293:1786-1790.
53. Paulander, W., S. Maisnier-Patin, and D. I. Andersson 2007. Multiple mechanisms to ameliorate the fitness burden of mupirocin resistance in Salmonella typhimurium. Molecular Microbiology 64:1038-1048.
54. Perron, G. G., M. Zasloff, and G. Bell 2006. Experimental evolution of resistance to an antimicrobial peptide. Proceedings of the Royal Society B: Biological Sciences 273:251-256.
55. Pym, A. S., B. Saint-Joanis, and S. T. Cole 2002. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infection and Immunity 70:4955-4960.
56. R Core Team. 2013. R: A Language and Environment for Statistical Computing. R Core Team.
57. Ramadhan, A. A., and E. Hegedus 2005. Survivability of vancomycin resistant Enterococci and fitness cost of vancomycin resistance acquisition. Jounal of Clinical Pathology 58:744-746.
58. Salyers, A. A., and C. F. Amabile-Cuevas 1997. Why are antibiotic resistance genes so resistant to elimination ? Antimicrobial Agents and Chemotherapy 41:2321-2325.
59. Sander, P., B. Springer, T. Prammananan, A. Sturmfels, M. Kappler, M. Pletschette, and C. Böttger 2002. Fitness cost of chromosomal drug resistance-conferring mutations fitness. Antimicrobial Agents and Chemotherapy 46:1204-1211.
60. Schrag, S. J., and V. Perott 1996. Reducing antibiotic resistance. Nature 381:120-121.
61. Schwarzer, G. 2013. Meta: meta-analysis with R.
62. Seppala, H., T. Klaukka, J. Vuopio-Varkila, A. Muotiala, H. Helenius, K. Lager, P. Huovinen, and The Finish Study Group for Antimicrobial Resistance 1997. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A Streptococci in Finland. The New England Journal of Medicine 337:441-446.
63. Sousa, A., S. Magalhães, and I. Gordo 2012. Cost of antibiotic resistance and the geometry of adaptation. Molecular Biology and Evolution 29:1417-1428.
64. Springer, B., Y. G. Kidan, T. Prammananan, K. Ellrott, E. C. Böttger, and P. Sander 2001. Mechanisms of streptomycin resistance: selection of mutations in the 16S rRNA gene conferring resistance. Antimicrobial Agents and Chemotherapy 45:2877-2884.
65. Stickland, H. G., P. W. Davenport, K. S. Lilley, J. L. Griffin, and M. Welch 2010. Mutation of nfxB causes global changes in the physiology and metabolism of Pseudomonas aeruginosa. Journal of Proteome Research 9:2957-2967.
66. Sundqvist, M., P. Geli, D. I. Andersson, M. Sjölund-Karlsson, A. Runehagen, H. Cars, K. Abelson-Storby et al. 2010. Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use. The Journal of Antimicrobial Chemotherapy 65:350-360.
67. Trindade, S., A. Sousa, K. Bivar Xavier, F. Dionisio, M. G. Ferreira, and I. Gordo 2009. Positive epistasis drives the acquisition of multidrug resistance. PLoS Genetics 5:e1000578.
68. de Vos, M., B. Muller, S. Borrell, P. A. Black, P. D. van Helden, R. M. Warren, S. Gagneux et al. 2013. Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. Antimicrobial Agents and Chemotherapy 57:827-832.
69. Walsh, C. 2003. Antibiotics: Actions, Origins, Resistance. ASM Press, Washington, DC.
70. Wang, M., J. H. Tran, G. A. Jacoby, F. Wang, and D. C. Hooper 2003. Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China. Antimicrobial Agents and Chemotherapy 47:2242-2248.
71. Wong, A., N. Rodrigue, and R. Kassen 2012. Genomics of adaptation during experimental evolution of the opportunistic pathogen Pseudomonas aeruginosa. PLoS Genetics 8:e1002928.
72. World Health Organization 2012. The Evolving Threat of Antimicrobial Resistance Options for Action. World Health Organization.
73. Yu, J., J. Wu, K. P. Francis, T. F. Purchio, and J. L. Kadurugamuwa 2005. Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. The Journal of Antimicrobial Chemotherapy 55:528-534.